Antibody type
Monoclonal antibodies
Immunogen
Synthesized peptide derived from human TCL1
Specificity
The antibody can specifically recognize human TCL1 protein.
Constitute
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.153% sodium azide.
Source
Mouse, Monoclonal/IgG2a, Kappa
Dilution rate
IHC-p 1:100-500, IF 1:100-500
Purification process
The antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen.
Other name
T-cell leukemia/lymphoma protein 1A (Oncogene TCL-1;Oncogene TCL1;Protein p14 TCL1)
Background
Overexpression of the TCL1 gene in humans has been implicated in the development of mature T cell leukemia, in which chromosomal rearrangements bring the TCL1 gene in close proximity to the T-cell antigen receptor (TCR)-alpha (MIM 186880) or TCR-beta (MIM 186930) regulatory elements (summarized by Virgilio et al., 1998 [PubMed 9520462]). In normal T cells TCL1 is expressed in CD4-/CD8- cells, but not in cells at later stages of differentiation. TCL1 functions as a coactivator of the cell survival kinase AKT (MIM 164730) (Laine et al., 2000 [PubMed 10983986]).[supplied by OMIM, Jul 2010],
Function
disease:Chromosomal aberrations activating TCL1A are found in chronic T-cell leukemias (T-CLL). Translocation t(14;14)(q11;q32); translocation t(7;14)(q35;q32); inversion inv(14)(q11;q32) that involves the T-cell receptor alpha/delta locuses.,function:Enhances the phosphorylation and activation of AKT1, AKT2 and AKT3. Promotes nuclear translocation of AKT1. Enhances cell proliferation, stabilizes mitochondrial membrane potential and promotes cell survival.,similarity:Belongs to the TCL1 family.,subcellular location:Microsomal fraction.,subunit:Homodimer. Interacts with AKT1, AKT2 and AKT3 (via PH domain). Interacts with PNPT1; the interaction has no effect on PNPT1 exonuclease activity.,tissue specificity:Restricted in the T-cell lineage to immature thymocytes and activated peripheral lymphocytes. Preferentially expressed early in T- and B-lymphocyte differentiation.,
